PureTech to Present Phase 1b LYT-200 Results at ESMO 2026
PureTech announced that results from the completed Phase 1b trial of LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia will be presented at ESMO 2026.